Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spruce Biosciences, Inc. (SPRB : NSDQ)

• Company Description    Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $51.08 Daily Weekly Monthly 20 Day Moving Average: 50,756 shares Shares Outstanding: 2.75 (millions) Market Capitalization: $140.57 (millions) Beta: 3.26 52 Week High: $240.00 52 Week Low: $7.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.43% -10.05% 12 Week -12.77% -19.36% Year To Date -41.37% -44.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 611 GATEWAY BOULEVARD SUITE 740 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-655-4168 fax: - investors@sprucebio.com http://www.sprucebiosciences.com

• General Corporate Information    Officers Javier Szwarcberg - Chief Executive Officer Michael Grey - Executive Chairman Samir Gharib - President and Chief Financial Officer Camilla V. Simpson - Director Daniel Spiegelman - Director Peer Information Spruce Biosciences, Inc. (CORR.) Spruce Biosciences, Inc. (RSPI) Spruce Biosciences, Inc. (CGXP) Spruce Biosciences, Inc. (BGEN) Spruce Biosciences, Inc. (GTBP) Spruce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 85209E208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 2.75 Most Recent Split Date: 8.00 (0.01:1) Beta: 3.26 Market Capitalization: $140.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-7.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-31.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.06 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 62.84% vs. Previous Quarter: 6.68% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -155.40 12/31/25 - -203.99 09/30/25 - -305.39 ROA 03/31/26 - -101.67 12/31/25 - -127.96 09/30/25 - -168.01 Current Ratio 03/31/26 - 4.67 12/31/25 - 5.17 09/30/25 - 1.54 Quick Ratio 03/31/26 - 4.67 12/31/25 - 5.17 09/30/25 - 1.54 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - -6,869.30 Book Value 03/31/26 - 12.59 12/31/25 - 39.72 09/30/25 - 10.73 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.16 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 13.62 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©